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College of Rheumatology criteria for 20% improvement (ACR20 criteria). Data was
obtained from a comprehensive literature review using PubMed, Medline, and
Cochrane library. Efﬁ cacy values were obtained from published randomized clinical 
trials. A decision tree analyses was conducted followed by one-way and two-way 
sensitivity analyses. Costs and efﬁ cacy values associated with therapeutic options were 
varied in the sensitivity analyses. RESULTS: The probability of achieving ACR20
response for ETANMTX, ADALMTX, INFLMTX, and MTX were 85.5%, 
65.95%, 61.26%, and 39.94%, respectively. The probability of an adverse drug event 
occurrence for ETANMTX, ADALMTX, INFLMTX, and MTX were 14.0%, 
6.5%, 7.9%, and 9.5%, respectively. The analysis revealed that ETANMTX option 
was the most cost-efﬁ cacious, with an annual cost of $52,369 to the patient. The
annual cost savings with ETANMTX combination use would be $19,318. Annual
costs of ADALMTX, INFLMTX, and MTX monotherapy were $79,058, $68,932, 
and $67,071 respectively. Results were robust to both one-way and two-way analysis. 
CONCLUSIONS: Etanercept plus Methotrexate combination therapy was a better 
option based on the ACR 20 outcome measure considered. An analysis using real
world data and/or a prospective head-to-head comparison study could provide better 
conclusive evidence for decision-makers.
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OBJECTIVES: An observational study comparing risedronate to alendronate (REAL) 
in a subgroup of postmenopausal osteoporotic (PMO) women with prior fracture
demonstrated that treatment with risedronate reduced the incidence of hip fracture by
66% in the ﬁ rst year of treatment (Delmas, 2008). The objective of this analysis was 
to determine the cost-effectiveness of risedronate compared to alendronate at generic
pricing using these effectiveness data in a high risk PMO population in the U.S. 
METHODS: A validated Markov model of osteoporosis (Tosteson, 2001) was used 
to estimate the impact of therapy on hip fractures, costs, and quality-adjusted life
years (QALYs). The model simulated a cohort of 1000 women ages 65 with 
BMDa2.5 and a previous vertebral fracture, treated with risedronate or alendronate
for one year. Associated costs and QALYs were tracked for an additional two years 
in each arm. Hip fracture incidence and mortality rates, as well as drug (generic alen-
dronate 93.5% lower than risedronate) and hip fracture costs were extracted from
published literature. RESULTS: In a cohort of 1000 women treated with risedronate 
versus alendronate, the model predicted 25 fewer hip fractures and 8.41 additional 
QALYs, resulting in a cost savings of $330,378. Extrapolating to a population of PMO 
women with a prior vertebral fracture in the U.S. suggests that risedronate prevents
over 114,000 fractures in roughly 4.6 million women at cost savings of over $1,515 
million. A sensitivity analysis assuming treatment for 2 years and parity efﬁ cacy in
year 2 resulted in a cost per QALY gained for earlier fracture protection of $9925
(cost per fracture averted: $3419) when treating with risedronate versus alendronate
in the population 65. Risedronate remains cost-saving in the 80 population. CON-
CLUSIONS: Based on “real world” data this analysis suggests risedronate’s early
fracture protection results in favorable cost-effectiveness versus generic alendronate
despite its higher drug cost.
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TREATMENT WITH NSAIDS – A DETERMINATION AND
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OBJECTIVES: To determine and quantify the key drivers of cost-effectiveness in 
osteoarthritis (OA) treatment with traditional NSAIDs and COX-2 selective pharma-
ceuticals. METHODS: Cost effectiveness analysis (CEA) in OA treatment with tradi-
tional NSAIDs and COX-2 selective pharmaceuticals focus on side effects given the 
non-signiﬁ cant differences in efﬁ cacy (pain relief) among treatments. The most fre-
quently included side-effects and complications in OA CEA analysis are gastrointesti-
nal (GI) complications and myocardial infarction (MI). Given the concern about
broader cardiovascular (CV) risks associated with NSAID treatment, the scope of a
recently published Markov model (ﬁ ve-year horizon, three-month cycles, health care
perspective) was expanded to include four additional CV events (stroke, coronary
insufﬁ ciency, venous thromboembolism and angina). Two treatments priced at 1) the 
average of celecoxib and etoricoxib, and 2) ibuprofen were evaluated. The model was 
populated with UK data. Absolute and relative GI risks were derived from a recent 
NICE HTA report whereas absolute CV risks were assumed to equal the normal 
population risk and relative CV risks were taken from the literature. The model was 
used to determine the most important drivers of cost-effectiveness in OA treatment. 
This was done by evaluating the responsiveness of the ICER to a 1% change in the 
input variable of interest, controlling for changes in all other variables. RESULTS:
The ﬁ ve most inﬂ uential variables were (% impact on ICER resulting from 1% change
in the variable): Quality of life in arthritis (2.5%), relative risk of CV events (1.5%), 
relative risk of mild GI events (1.3%), price of the COX-2 pharmaceutical (1.3%) and 
quality of life in dyspepsia (0.7%). CONCLUSIONS: Whilst the most important cost-
effectiveness driver in OA treatment is overall quality of life changes, the analysis
indicate that there might be higher economic beneﬁ ts associated with decreasing CV 
risks rather than decreasing aspects of GI risk.
PMS26
CHARACTERISTICS AND HEALTH CARE UTILIZATION
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OBJECTIVES: Injection site reactions (ISR) are the most common type of adverse 
event associated with the subcutaneous use of the tumor necrosis factor inhibitor 
(Anti-TNF) agents, etanercept (Enbrel) and adalimumab (Humira). The purpose of 
this study was to 1) investigate the incidence and characteristics of ISR, and 2) capture
the humanistic and economic consequences of ISR in patients who received etanercept
and/or adalimumab for rheumatoid arthritis (RA). METHODS: RA patients were 
identiﬁ ed through a query of outpatient claims with an ICD-9 code for RA and prac-
tice code for Jefferson Rheumatology Associates, Philadelphia, PA. Patients who met 
inclusion criteria of q18 years old and having received etanercept or adalimumab in
the past 3 years were administered a one-time observational survey developed by the 
investigators. RESULTS: The study included thirty patients, ﬁ ve of which had used
both adalimumab and etanercept. The overall prevalence of ISR was 56.3% (9
patients, n  16) for adalimumab and 84.2% (16 patients, n  19) for etanercept. 
Clinical characteristics of ISR included erythema (44.4%–68.8%), pruritus (44.4%–
68.8%), and swelling (33.3%–56.3%). Only one patient (3.3%) in the cohort was 
pre-medicated for ISR. Three patients in the adalimumab (n  9, 33.3%) and one 
patient in the etanercept group (n  16, 6.25%) called their physician when experienc-
ing a ﬁ rst-time ISR. Ice was the most common form of treatment for the ﬁ rst, typical, 
and worst incidence of ISR. No patients reported going to the ER, taking antihista-
mines, or using analgesics to treat ISR. Two patients (22.2%) and no patients discon-
tinued therapy due to ISR in the adalimumab and etanercept group, respectively. No
missed work-days were reported in either group due to ISR. CONCLUSIONS: ISR 
occurred in over half of the patient cases studied, and was largely characterized by 
erythema, pruritis, and swelling. Patient counseling about ISR is essential since self-
treatment is common and discontinuation may result.
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OBJECTIVES: Psoriatic arthritis (PsA) is an inﬂ ammatory arthritis occurring in about 
10–30% of the patients with psoriasis. Registration of highly effective but costly bio-
logical drugs for the treatment of PsA gave an extra impulse to economic evaluations
in rheumatology. There are no data on cost-of-illness of PsA neither from Hungary 
nor from countries with similar economic status (i.e. Poland, Slovakia and Czech 
Republic). The main goal of present study was to collect data on disease burden and 
costs of patients with PsA in Hungary. METHODS: A cross sectional questionnaire
survey of consecutive patients aged q18 years with diagnosis of PsA was conducted 
in 8 hospital based rheumatology outpatient centres in Hungary in 2008. Data were 
collected by rheumatologists during routine outpatient visits. Observed variables were 
demographic data, disease duration, disease activity score (DAS28), psoriasis area
severity index (PASI), drug use, the use of aids and devices, imaging, gastroscopy, 
outpatient visit, admissions to hospital, orthopaedic surgery, spa, physiotherapy, home 
care, transportation, non-reimbursed health care services, home remodelling and infor-
mal care. Data on PsA related reduction of working hours, sick leave and disability 
pension were collected also. RESULTS: A total of 183 patients were enrolled, of these, 
104 (57%) were women. The mean age of the sample was 50.3 (SD 12.9) years and 
the mean disease duration was 9.2 (9.2) years. The annual average direct, indirect and 
total costs were 2 670, 2 904 and 5 574 euros/patient/year in PsA, respectively. The 
main cost domains were the productivity losses due to work disability (49%) and the 
costs of biologic therapies (18%), with 2 742 (SD 4 920) and 1 008 (SD 4 134) 
euros/patient/year, respectively. CONCLUSIONS: Our study showed that the eco-
nomic burden of PsA is considerable in Hungary and provided a baseline to evaluate 
the economic effect of treatments in PsA.
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OBJECTIVES: Assess direct (medical and drug) and indirect (workloss) costs of 
osteoporotic patients with non-vertebral (NV) fractures. METHODS: Osteoporosis 
patients (ICD-9-CM code 733.0) were identiﬁ ed (1999–2006) from an employer
claims database (^8,000,000 privately-insured beneﬁ ciaries; ages 18–64) and the
Medicare Standard Analytic Files 5% sample (ages 65). Osteoporotic patients with 
NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib, or hip) were randomly 
matched on age, gender, employment status, and geography to osteoporotic controls. 
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Annual direct costs were calculated (by third-party payer perspective) for privately-
insured (n  4,764) and Medicare (n  48,742; medical costs only) beneﬁ ciaries. Indi-
rect costs were calculated for privately-insured employees with disability data (n 
1148). Costs were reported in 2006 dollars. RESULTS: In Medicare, mean medical
costs per non-vertebral, non-hip (NVNH) fracture patient were $7,463 in excess of 
controls ($13,720 vs. $6,258; p  0.01).The most expensive patients had fractures of 
the hip, multiple sites, and femur (excess costs of $25,120; $20,049; $19,213, respec-
tively). Aggregate annual excess medical costs of these NVNH patients (n  35,933)
were $268.1 million versus $200.9 million for hip fracture patients (n  7,997)
(excludes patients with hip and NVNH on index date). In the privately-insured popu-
lation, excess mean direct costs per NVNH fracture patient were $5,381 ($11,090 vs.
$5,709; p  0.01). The most expensive patients had fractures of the hip, multiple sites, 
and pelvis (excess costs of $13,801; $9,642; and $8,164, respectively). Aggregate
annual excess direct costs of these NVNH patients (n  4478) were $24.1 million 
versus $3.5 million for hip fracture patients (n  255). Mean excess indirect costs per
NV employee were $1956 ($4,349 vs. $2393; p  0.01). CONCLUSIONS: Excess 
direct and indirect costs of NV osteoporotic fracture patients to payers are substantial.
While hip fracture patients are more costly per patient, NVNH fracture patients are
associated with a larger percentage of fractures and aggregate excess costs for both 
these privately-insured and Medicare samples.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on time lost from work 
in patients with rheumatoid arthritis (RA). METHODS: The effect of GLM on time 
lost from work (days) was prospectively evaluated in 3 multicenter, randomized,
double-blind, placebo-controlled studies in patients with RA. Pooled data from 
patients receiving any injection of study agent (GLM or placebo) with or without 
methotrexate (MTX) in 3 RA studies (GO-BEFORE, GO-FORWARD, and GO-
AFTER) were included. GLM SC injections of 50 or 100 mg were administered q4 
weeks. Time lost from work for patients was collected through a questionnaire at 
baseline and q8 weeks through week 24 and was summarized cumulatively through 
week 24 with comparisons between groups using ANOVA on van der Waerden normal 
scores. The proportion of patients reporting no time lost from work in the GLM /
MTX group was compared with the PBO / MTX group using the chi square test.
RESULTS: Through week 24, signiﬁ cant differences in time lost from work were 
observed between the GLM / MTX group and the PBO / MTX group. At week 
24, the PBO / MTX group lost 6.9 o 19.7 days compared with 5.0 o 19.4 days for
the combined GLM /MTX group. At week 24, the 75th percentile for the combined 
GLM /MTX group was 1.000 day (range 0–180) compared with 3.000 days (range
0–120) for the PBO / MTX group. A signiﬁ cantly higher proportion of patients in 
the combined GLM / MTX group reported no time lost from work compared with
the PBO / MTX group (73.1% vs. 60.7%; p  0.002). CONCLUSIONS: GLM /
MTX signiﬁ cantly reduced time lost from work for patients with RA compared with 
PBO / MTX.
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THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: 
ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
2005 AND 2006 DATA
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OBJECTIVES: Previous research reported the prevalence and health care and
productivity cost of rheumatoid arthritis (RA) using Medical Expenditure Panel
Survey (MEPS) 2004 data; this study replicates the analyses using 2005 and 2006 
data. METHODS: MEPS, a comprehensive survey of approximately 35,000 individu-
als in the US, was used to identify non-institutionalized US persons with RA. Multiple 
linear and semi-log regressions were applied to estimate total annual health care
expenditure and income (yearly wages) associated with RA. Covariates in the expen-
diture equations included demography, comorbidities, and overall health status.
Semi-log regression for income renders the distribution of income symmetric. Covari-
ates in the income equations included demography, comorbidities, education, occupa-
tion, and health status. RESULTS: A total of 150 and 148 patients with RA were 
identiﬁ ed in 2005 and 2006 versus 136 in 2004; 75% (2005) and 80% (2006) were 
women versus 76% (2004), and 53% (2005) and 50% (2006) of RA patients 
were between the ages 41–64 years versus 56% in 2004. Linear regressions demon-
strated that the incremental increase in health care cost associated with RA was
$2902 (P  0.0001) in 2005 and $1882 (P  0.003) in 2006, versus $4422 (2004). 
Semi-logarithmic regression explaining wages in 2005 and 2006 had adjusted R2 of 
56% and 59%. RA signiﬁ cantly reduced wages by $2207 (0.9237 log estimate)
annually (P  0.0001) in 2005 and $1,559 (0.5038 log estimate; P  0.05) in 2006; 
wages of RA patients in 2004 were reduced by $3526 (1.088 log estimate). CON-
CLUSIONS: The economic impact of RA is substantial to both income loss and health 
care costs. Replication and validation of outcomes research are important to establish
the precision of statistical associations as well as changes across time. Further study
will explore whether changes in the care of patients with RA affect changes in out-
comes over time.
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OBJECTIVES: Fibromyalgia syndrome (FMS) is a chronic disorder deﬁ ned by wide-
spread musculo-skeletal pain that is often associated with a number of comorbidities 
including fatigue, sleep disturbance, stiffness and functional limitation. In absence of 
a speciﬁ c diagnostic test, FMS is typically difﬁ cult to identify, and there is limited 
knowledge about the economic burden of FMS. The objectives of this study were to
estimate prevalence of comorbidities, health care resources utilization and costs associ-
ated with FMS. METHODS: A retrospective cohort study was conducted using data 
from the Quebec provincial health plan (RAMQ) for a random sample of patients
with two or more recorded diagnoses of FMS and a control cohort without FMS,
matched for age and gender, for a period spanning from June 2006 to July 2007. 
Prevalence of comorbidities was estimated and a chronic disease score was calculated.
Health care resources consumed by FMS and non-FMS patients included visits to 
physicians, physician’s interventions, pain-related medications, non-pain-related medi-
cations and hospitalizations. RESULTS: A total of 16,010 FMS patients were identi-
ﬁ ed, with a matched number of control patients. The mean age of the study population 
was 58.8 years and most subjects were women (67.8%). The prevalence of most
comorbidities and the chronic disease score were signiﬁ cantly greater in the FMS 
patients than in control group (3.8 vs. 2.8; p  0.001). Health resources utilization
during the study period was signiﬁ cantly greater among FMS patients than non-FMS 
patients: the annual number of physician visits and interventions was 25.1 for FMS
vs. 14.8 for non-FMS patients. The amount paid by the RAMQ was signiﬁ cantly
greater for patients with FMS ($4065) compared to patients without FMS ($2766, 
p  0.001). CONCLUSIONS: This analysis of the RAMQ database indicated that
comorbidities are highly prevalent in FMS patients, and suggested that the economic 
burden associated with FMS is substantial.
PMS32
HIGHER OUT-OF-POCKET PHARMACY EXPENSE IS ASSOCIATED WITH
HIGHER SWITCHING RATES AMONG ANTI-TUMOR NECROSIS FACTOR
IN PATIENTS WITH RHEUMATOID ARTHRITIS
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OBJECTIVES: To evaluate the relationship between out-of-pocket (OOP) pharmacy
expenses and switching rates among anti-tumor necrosis factor (anti-TNF) agents in 
patients with rheumatoid arthritis (RA). METHODS: This retrospective study utilized 
claims for RA patients from the PharMetrics Patient Centric database. The index 
biologic date was deﬁ ned as the ﬁ rst anti-TNF claim between January 1, 2000 and 
December 31, 2006. A minimum of 30 months of continuous plan eligibility was 
required: 6 months prior to and 24 months following the index biologic date. Patients
were followed for 24 months after the index biologic date. Switching among anti-
TNFs (inﬂ iximab, etanercept, or adalimumab) was recorded. The pharmacy OOP 
expense was deﬁ ned as the allowed amount minus amount paid. The annual OOP of 
$500 was used as a cut point to deﬁ ne the high and low OOP groups. RESULTS: A
total of 3,086 patients were analyzed (74.5% female; mean age  49.9 years). Half 
(1597; 51.7%) had an annual pharmacy OOP $500. The mean and median annual 
OOP expenses for the study population were $929 and $528, respectively. During the 
study period, 465 (15.1%) patients switched to a different anti-TNF agent. Compared 
to the lower OOP expense group, patients in the higher OOP group had a higher 
switching rate (18.0% versus 12.0%, p  0.0001), and shorter time to switch (329
days versus 352 days, p  0.230). In the logistic regression, after controlling for age, 
gender, co-morbidity, and disease staging, patients in the high OOP group had signiﬁ -
cantly higher switching rate (odds ratio 1.60, 95% conﬁ dence interval 1.30–1.96).
CONCLUSIONS: Higher OOP expenses were associated with higher rates of switch-
ing among the anti-TNF agents in the RA patient population. Decision makers may 
consider such ﬁ ndings in the beneﬁ t design of this therapeutic class.
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OBJECTIVES: The purpose of this study was to estimate the expected medical cost
of a single conservative medical management (CMM) per patient with osteoporotic 
vertebral compression fracture (VCF) in Japan. METHODS: A questionnaire survey
was conducted for Japanese orthopedic surgeons who mainly provide CMM for 
patients with VCF during their daily clinical practices, and who consented to
participating in the survey. Responses to the questionnaire were summarized and
the expected medical costs for each therapeutic regimen until recovery per patient
